Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial
暂无分享,去创建一个
C. Cannon | D. McGuire | R. Pratley | S. Dagogo-Jack | R. Frederich | A. Pong | D. Cherney | M. Maldonado | Chih-Chin Liu | Francesco Cosentino | F. Cosentino
[1] B. Zinman,et al. Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. , 2020, Kidney international.
[2] B. Zinman,et al. Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. , 2020, Kidney international.
[3] C. Cannon,et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. , 2020, The New England journal of medicine.
[4] S. Heyman,et al. Fasting-Induced Natriuresis and SGLT: A New Hypothesis for an Old Enigma , 2020, Frontiers in Endocrinology.
[5] B. Zinman,et al. Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. , 2020, Journal of the American Society of Nephrology : JASN.
[6] Y. Seino,et al. Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, preserves renal function irrespective of acute changes in the estimated glomerular filtration rate in Japanese patients with type 2 diabetes , 2020, Hypertension Research.
[7] H. Heerspink,et al. The new biology of diabetic kidney disease - mechanisms and therapeutic implications. , 2020, Endocrine reviews.
[8] F. Geurts,et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. , 2019, Kidney international.
[9] H. Heerspink,et al. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes , 2019, Diabetes Care.
[10] H. Nagasu,et al. Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging. , 2019, Circulation.
[11] C. Cannon,et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS‐CV) , 2018, American heart journal.
[12] B. Zinman,et al. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. , 2018, Journal of the American Society of Nephrology : JASN.
[13] H. Heerspink,et al. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. , 2018, Kidney international.
[14] W. Tamborlane,et al. Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes , 2018, Diabetes Care.
[15] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59 , 2017, Kidney international supplements.
[16] J. Scholey,et al. Plasma uric acid effects on glomerular haemodynamic profile of patients with uncomplicated Type 1 diabetes mellitus , 2016, Diabetic medicine : a journal of the British Diabetic Association.
[17] B. Perkins,et al. Uric acid as a biomarker and a therapeutic target in diabetes. , 2015, Canadian journal of diabetes.
[18] B. Perkins,et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. , 2015, American journal of physiology. Renal physiology.
[19] U. Broedl,et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.
[20] Merlin C. Thomas,et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. , 2011, Kidney international.